Results of a Phase 3 clinical trial of guselkumab shows improvement in all minimal disease activity in adults with psoriatic arthritis.
A recent study of four patients with disabling pansclerotic morphea has revealed they share an overactive version of a protein called STAT4.
The European Commission has approved Novartis’ secukinumab (Cosentyx®) for the treatment of hidradenitis suppurativa (HS) in adults.
The FDA has approved Galderma’s Restylane Eyelight for the treatment of undereye hollows in adults aged 21 years and over.
Allergan Aesthetics, an AbbVie company, has announced that the FDA has approved their SKINVIVE™ by JUVÉDERM®.
Dermavant announces positive results from their ADORING 1 study evaluating the efficacy and safety of topical VTAMA® (tapinarof) cream, 1%.
The FDA has approved Vyjuvek (beremagene geperpavec-svdt), for the treatment of dystrophic epidermolysis bullosa (DEB).
Results from a phase 2 study of gusacitinib have demonstrated significant improvement in patients with chronic hand eczema.
The FDA has accepted the New Drug Application for investigational IDP-126 gel for the treatment of acne vulgaris.
Two phase 3 trials evaluated the use of Dupixent (dupilumab) in the treatment of prurigo nodularis in adults.
The FDA has approved Sculptra®, Galderma’s injectable poly-L-lactic acid to correct fine lines and wrinkles in the cheek area.
April W. Armstrong, MD, MPH appointed chief of the division of dermatology at University of California Health.
Tralokinumab clinical trial shows drug was well tolerated and efficacious in adolescents with moderate-to-severe atopic dermatitis (AD).
Researchers sought to understand patient perspectives relating to their experience, expectations, and preferences of psoriasis treatment.
The FDA has cleared Candesant Biomedical’s Brella™, a SweatControl Patch for the treatment of primary axillary hyperhidrosis in adults.
Arcutis Biotherapeutics has announced the FDA has accepted their NDA for roflumilast foam 0.3% for the treatment of seborrheic dermatitis.
A randomized phase 2 study evaluated the safety, efficacy, and tolerability of IDP-126 in pediatric patients with moderate-to-severe acne.
A group of 10 board-certified dermatologists conducted a Delphi consensus to evaluate the best methods for managing AMH.
The 2023 AAD Annual Meeting was buzzing with exciting news and breakthrough studies. Check out some of the latest clinical updates.
FDA to review supplemental Biologics License Application for Dupixent® (dupilumab) for chronic spontaneous urticaria (CSU).
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
